Awakn Life Sciences Past Earnings Performance
Past criteria checks 0/6
Awakn Life Sciences has been growing earnings at an average annual rate of 14.6%, while the Biotechs industry saw earnings growing at 16.6% annually. Revenues have been growing at an average rate of 74.3% per year.
Key information
14.6%
Earnings growth rate
24.2%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | 74.3% |
| Return on equity | n/a |
| Net Margin | -4,201.6% |
| Last Earnings Update | 31 Jan 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Awakn Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jan 24 | 0 | -4 | 3 | 1 |
| 31 Oct 23 | 2 | -7 | 5 | 1 |
| 31 Jul 23 | 2 | -8 | 5 | 1 |
| 30 Apr 23 | 2 | -8 | 5 | 1 |
| 31 Jan 23 | 0 | -5 | 4 | 1 |
| 31 Oct 22 | 0 | -8 | 5 | 3 |
| 31 Jul 22 | 0 | -10 | 6 | 3 |
| 30 Apr 22 | 0 | -18 | 7 | 4 |
| 31 Jan 22 | 0 | -16 | 6 | 3 |
| 31 Oct 21 | 0 | -13 | 4 | 2 |
Quality Earnings: AWKN is currently unprofitable.
Growing Profit Margin: AWKN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if AWKN's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare AWKN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AWKN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: AWKN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.